ReviewCellular and molecular life sciences : CMLS2019
Molecular pathways of nonalcoholic fatty liver disease development and progression.
Review in Cellular and molecular life sciences : CMLS, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 335 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
335 citing papers in PubMed, 7 syntheses or guidelines pooled it, 588 citations in OpenAlex.
- High Remnant Cholesterol Increased the Risk of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) or Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review and Meta-Analysis.Journal of the ASEAN Federation of Endocrine Societies · 2026Pooled it
- Frontiers and emerging trends in research on metabolic syndrome and metabolic dysfunction-associated fatty liver disease: a bibliometric analysis (2005-2024).Frontiers in endocrinology · 2026Pooled it
- Comparative efficacy of drugs with different mechanistic pathways/targets in the treatment of pediatric NAFLD: evidence from a Bayesian network meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Efficacy and safety of GLP-1 receptor agonists in patients with metabolic-associated fatty liver diseases: an umbrella review.Frontiers in medicine · 2026Pooled it
- A Systematic Review of the Beneficial Effects of Berry Extracts on Non-Alcoholic Fatty Liver Disease in Animal Models.Nutrition reviews · 2025Pooled it
- The benefit of metformin in the treatment of pediatric non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.European journal of pediatrics · 2023Pooled it
- Relationship ofCanadian journal of gastroenterology & hepatology · 2023Pooled it
- Trial
- Hypothyroidism and Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanisms, Clinical Links, and Therapeutic Implications.Current obesity reports · 2026Review
- Article
- Inflammation burden index as a complementary marker for the assessment of hepatic steatosis and fibrosis: evidence from NHANES 2017-2018.Abdominal radiology (New York) · 2026Article
- Network Pharmacology and In Vivo Validation Reveal Berberine-Mediated Regulation of the Liver-Brain Inflammatory Axis in MCD-Induced Steatohepatitis.International journal of molecular sciences · 2026Article
- Indole-3-Propionic Acid Alleviates Metabolic Dysfunction-Associated Fatty Liver Disease via AHR/AMPK Signaling Activation.Food science & nutrition · 2026Article
- Deciphering cytochrome P450 reductase role in MASLD: molecular mechanisms and pathophysiological implications.Nature reviews. Gastroenterology & hepatology · 2026Review
- Design, synthesis, and biological evaluation of quinoxalinyl and quinolinyl derivatives as ALK5 inhibitors.Molecular diversity · 2026Article
- MASLD and Pancreatic Diseases: From Shared Mechanisms to Clinical Implications and Future Directions.Nutrients · 2026Review
- Oleanolic Acid Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Inhibiting Ferroptosis through Targeting PTGS2 as a Key Molecular Node and Activating the AMPK/ACC Signaling Pathway.Journal of agricultural and food chemistry · 2026Article
- Isoferulic acid alleviates LPS/D-galactosamine-induced acute liver injury in mice by inhibiting ERK/NF-κB signaling and modulating the NLRP3 inflammasome.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- MCD biomarkers Egfr, Hmox1, Lgmn identified in NAFLD.BMC endocrine disorders · 2026Article
- Gut Mycobiota-Associated Tryptophan Catabolites Protect Against Metabolic Dysfunction-Associated Steatotic Liver Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
275 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a main hepatic manifestation of metabolic syndrome. It represents a wide spectrum of histopathological abnormalities ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) with or without fibrosis and, eventually, cirrhosis and hepatocellular carcinoma. While hepatic simple steatosis seems to be a rather benign manifestation of hepatic triglyceride accumulation, the buildup of highly toxic free fatty acids associated with insulin resistance-induced massive free fatty acid mobilization from adipose tissue and the increased de novo hepatic fatty acid synthesis from glucose acts as the "first hit" for NAFLD development. NAFLD progression seems to involve the occurrence of "parallel, multiple-hit" injuries, such as oxidative stress-induced mitochondrial dysfunction, endoplasmic reticulum stress, endotoxin-induced, TLR4-dependent release of inflammatory cytokines, and iron overload, among many others. These deleterious factors are responsible for the triggering of a number of signaling cascades leading to inflammation, cell death, and fibrosis, the hallmarks of NASH. This review is aimed at integrating the overwhelming progress made in the characterization of the physiopathological mechanisms of NAFLD at a molecular level, to better understand the factor influencing the initiation and progression of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.